Keva Q1 FY27: Double-digit growth, better margins, and a flavour-led quarter

S H Kelkar and Company Limited (Keva) opened FY27 with a clean set of operating numbers, driven by healthy demand across customer segments and the benefit of operating leverage. On a consolidated basis, revenue from operations rose 14.1% year-on-year to Rs. 662.4 crore in Q1 FY27, while EBITDA increased 21.3% to Rs. 88.7 crore. EBITDA margin expanded to 13.4% from 12.6% a year ago, even as the company continued to spend on its growing global Creative Development Centre (CDC) network and R&D capabilities.

Management’s commentary remained measured. The CEO highlighted that end-market demand drivers in fragrance and taste remain intact across personal care, home care and food categories, but flagged that geopolitical developments and trade volatility continue to warrant caution. The CFO added that gross margins were stable year-on-year, supported by product mix and proactive raw material planning.

The quarter in numbers

The company’s Q1 FY27 performance reflected strong top-line momentum and margin improvement, with an additional lift to reported profits from an exceptional insurance claim.

PBT and PAT growth benefited from an exceptional income of about Rs. 30 crore related to an insurance claim, which management said relates to a fire incident. The CFO stated the claim process is progressing well and the company expects full settlement within FY27.

Segment performance: Flavour outperformed, fragrance absorbed investment costs

Keva’s segment mix showed two clear trends during the quarter. First, the fragrance business continued to grow, especially in Europe and select international markets. Second, the flavour business delivered a sharp step-up in scale and profitability.

On an “excluding Global Ingredients” basis, fragrance revenue increased 9.0% year-on-year to Rs. 539 crore, but fragrance EBITDA declined 5.1% to Rs. 56 crore. Management attributed this moderation to higher operating expenses linked to strengthening R&D capabilities and expanding the global CDC network. The company has repeatedly positioned these spends as growth investments that should improve its ability to win larger briefs and respond to evolving customer requirements, but the near-term implication is pressure on segment profitability until revenues scale.

Flavour was the standout. Revenue rose to Rs. 112 crore from Rs. 69 crore, a 63.2% increase, while segment EBITDA jumped to Rs. 35 crore from Rs. 14 crore. Management acknowledged that some of the growth reflects timing of customer orders and advised investors to read it on an annualized basis rather than extrapolating from a single quarter. In the concall, the CEO indicated that a normal quarterly flavour run-rate could be around Rs. 95 crore to Rs. 96 crore, implying that roughly Rs. 10 crore to Rs. 15 crore of Q1 sales may have been preponed.

Global Ingredients remained weak. Revenue declined to Rs. 8 crore from Rs. 15 crore, and EBITDA moved to a loss of Rs. 2.3 crore. Management linked the softness to lower demand in select export markets and limited near-term visibility amid geopolitical uncertainty.

Geographically, the investor presentation showed that Europe and Rest of World were stronger than India on the fragrance side. India fragrance revenue growth was close to flat, which management linked to a high base and deliberate decisions on pricing discipline and exiting lower-margin business.

Capital allocation, working capital, and debt: building resilience while staying cautious

A major theme in management’s narrative was supply assurance in a volatile environment. The CFO highlighted that the company undertook a strategic inventory build-up to support business continuity, which helped keep service levels stable but increased working capital requirements.

This was visible in the balance sheet snapshot. As of June 30, 2026, net debt stood at Rs. 852 crore and net debt to equity was 0.65x. Cash and investments were Rs. 56 crore. Net worth was Rs. 1,400 crore.

Management reiterated that debt levels remain consistent with earlier guidance and that it remains committed to deleveraging over the medium to long term. In the concall, the CFO said net debt is expected to remain broadly at June levels, though it may rise slightly in September.

Capex commentary was also specific. Management indicated that European capex is completed and the Europe plant has been operational since May. For India, Vanvate commissioning is expected in the third quarter. The company also discussed further investments in Vanvate and Vashivali, with the timing of some spending dependent on demand conditions.

Depreciation is already elevated, reflecting the company’s ongoing capex cycle. The CFO stated depreciation is around Rs. 35 crore per quarter currently, and is expected to move to roughly Rs. 38 crore to Rs. 39 crore per quarter after Vanvate capitalization.

What management is guiding for FY27

While management did not provide a narrow numeric range for margins, the message was consistent across the investor presentation and the concall: FY27 should deliver double-digit revenue growth and improved margins, even if quarterly performance varies.

The CFO explicitly stated that the pace of revenue growth may vary by quarter based on timing of customer orders, raw material costs, product mix, and the phasing of operating expenses. However, management believes the underlying business momentum supports double-digit growth and improved margins for the full year.

One notable aspect of the discussion was the emphasis on developed market expansion. Management described investments in Germany, USA and UK as long-term bets, and shared an internal milestone of aiming for EBITDA breakeven around year three for each initiative. Germany, which started earlier, is expected to reach breakeven between this year and next, with USA and UK following thereafter.

Takeaways

Keva’s Q1 FY27 results showed a strong start, with consolidated revenue up 14% and EBITDA margin improving to 13.4%. The flavour segment delivered an outsized contribution, though management cautioned that part of the growth reflects timing. Fragrance growth remained healthy, but profitability absorbed higher operating costs tied to deliberate investments in R&D and CDC expansion.

The more debated part of the story is the balance sheet. Management clearly linked higher net debt to strategic inventory and capex, positioning it as a resilience and growth decision rather than a structural issue. The next few quarters will be important for tracking working capital normalization, the recovery trajectory of Global Ingredients, and whether the operating leverage from higher revenues can continue to offset the cost base linked to global expansion.